Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bosentan vs Pioglitazone for Insulin Resistance in PAH
NCT00825266Phase 2
Key facts
- Status
- Terminated
- Start
- Sep 2008
- Primary completion
- May 2010
- Countries
- 1
- Sponsor
- Stanford University
- Modality
- Nucleic Acid-Directed Small Molecules, Orthosteric Ligands
- Drugs
- pioglitazonebosentan
- Conditions
- insulin resistance (IR)
01
Overview
Phase 2, randomised, open-label trial of pioglitazone and bosentan in insulin resistance (IR), sponsored by Stanford University. Started Sep 2008; status: terminated.
02
Design
- Study design
- RandomizedOpen-label
03
Registry description
The purpose of this study is to evaluate 1) the incidence of insulin resistance (a pre-diabetic state) in patients with pulmonary hypertension, and 2) test the utility of a validated PH therapy (Tracleer) versus Pioglitazone in the treatment of those patients found to have insulin resistance.
Beyond the preview
Go deeper on NCT00825266.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00825266.